Laurion Capital Management
VC Fund
New York, United States
Laurion Capital Management is an investment firm that provides a multi-disciplinary approach to capital markets investing. To collect qualitative and quantitative perspectives and data points, the company's research and investing teams use a wide aperture. Laurion Capital Management pursues investment opportunities across a variety of assetclasses at the point where the qualitative and quantitative meet.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 7%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Laurion Capital Management invests in
Stages Laurion Capital Management invests in
Countries Laurion Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Biotechnology 18 (64%)
- Health Care 7 (25%)
- Life Science 5 (18%)
- Therapeutics 5 (18%)
- Pharmaceutical 5 (18%)
Stage
- Post-IPO Equity 7 (25%)
- Series B 5 (18%)
- Series D 4 (14%)
- Series A 3 (11%)
- Pre-Seed 2 (7%)
Country
- United States 17 (61%)
- United Kingdom 3 (11%)
- France 2 (7%)
- China 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Benjamin Smith
Founder & Partner
|
Founder & Partner | Total investments: 1 | Find email | |
|
Sheehan Maduraperuma
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aardvark Therapeutics
|
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017. | $85M / Series C / May 09, 2024 | |
Leap Therapeutics
|
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology. | $40M / Post-IPO Equity / Apr 10, 2024 | |
Cypherpunk Technologies (formerly Leap Therapeutics)
|
Cypherpunk Technologies is a biopharmaceutical company developing antibody therapies for cancer while simultaneously executing a digital-asset treasury strategy centered on Zcash. Their oncology pipeline includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK-1, and FL-501, another antibody in preclinical development. | $40M / Post-IPO Equity / Apr 10, 2024 | |
Pyxis Oncology
|
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novelantibody-based immunotherapies.It was founded in 2019 and is based in Boston, Massachusetts. | $50M / Post-IPO Equity / Feb 27, 2024 | |
Pepgen
|
PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic. | $80.1M / Post-IPO Equity / Feb 07, 2024 | |
COMPASS Pathways
|
Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression.Compass Pathways conducts clinical trials and research toassess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression. | $125M / Post-IPO Equity / Aug 16, 2023 | |
MerQube
|
MerQube is a cloud native indexing platform designed for designing, calculating, and disseminating financial indices at scale. In the growing space of passive (index-linked) indexing, MerQube provides robust financial indices in the areas of equities, futures and options and ESG and has the expertise that spans market-capitalization weightedindices to risk-premia, volatility, thematics, and ESG. | $22M / Series B / Jul 13, 2023 | |
Axoni
|
Axoni is a real-time data replication technology company serving the world’s largest financial institutions. Axoni’s platform enables rapid, reliable deployment of critical financial networks and automated, real-time data replication across market participants. Founded in 2017, the company serves banks, asset managers, hedge funds, and financialmarket infrastructure firms across the globe from offices in New York and London. | $20M / Venture - Series Unknown / Apr 26, 2023 | |
Opensee
|
Opensee, is a Paris-based fintech that is helping financial institutions turn their big data challenges into competitive advantage and unlock vital business-user-led opportunities. Opensee, formerly ICA, was started by a team of financial industry and technology experts frustrated at not being able to find a simple Big Data analytics solution thatwould enable them to easily and efficiently dive deeper into all their data and perform what-if-analysis on the hundreds of billions of data points they were handling - so they built their own. With Opensee, for the first time, financial institutions’ business users can directly harness 100% of their vast quantities of data instantly on demand. Opensee empowers data divers to analyse deeper and faster. DISCOVER HOW WE HELP FINANCIAL INSTITUTIONS: - Manage RISK IN CAPITAL MARKETS more efficiently and proactively - Manage COMMERCIAL & RETAIL BANKING resources and regulatory reports with consistency, speed and granularity - Leverage your TRANSACTION DATA to improve your market intelligence and execution process | $11.7M / Series A / Dec 15, 2022 | |
Recursion Pharmaceuticals
|
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to our mission is the Recursion Operating System, or Recursion OS,that combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate our programs. We are a biotechnology company scaling more like a technology company. | $150M / Post-IPO Equity / Oct 25, 2022 | |
| See all 28 investments → | |||
Co-Investors
Perceptive Advisors
6 deals together
RA Capital Management
6 deals together
Samsara BioCapital
5 deals together
Invus
4 deals together
Alexandria Venture Investments
3 deals together
Citi
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Laurion Capital Management invest in?
Laurion Capital Management invests primarily in Biotechnology, Health Care and Life Science startups, most often at Post-IPO Equity and Series B stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Laurion Capital Management?
Public channels for Laurion Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Laurion Capital Management?
The team at Laurion Capital Management includes Benjamin Smith (Founder & Partner) and Sheehan Maduraperuma (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
